Previous 10 | Next 10 |
2023-11-15 09:50:09 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SciSparc Ltd (NASDAQ: SPRC), Chemomab Therapeutics Ltd (NASDAQ: CMMB), Cellectis SA (NASDAQ: CLLS), AstraZene...
2023-11-15 06:45:38 ET Summary Solid Biosciences receives FDA clearance for clinical testing of DMD gene therapy. Chevron is reviewing options for its Texas Haynesville shale assets, including a potential sale. U.S. House passes spending bill to avoid government shutdown, Sena...
2023-11-14 17:54:03 ET Gainers: Solid Biosciences ( SLDB ) +34% . CorMedix ( CRMD ) +20% . Arcturus Therapeutics ( ARCT ) +14% . Frequency Electronics ( FEIM ) +8% . Collective Audience ( CAUD ) +7% . Lose...
2023-11-14 17:05:16 ET More on Solid Biosciences Solid Biosciences reports Q3 results Solid Bio draws new Overweight rating at Cantor on valuation Seeking Alpha’s Quant Rating on Solid Biosciences Historical earnings data for Solid Biosciences ...
– Planning to initiate Phase 1/2 trial in pediatric DMD Patients – – First cohort to study patients 4 to < 6 years of age – CHARLESTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing prec...
CHARLESTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the J...
Solid Biosciences Inc. (SLDB) is expected to report $-1.2 for Q3 2023
– IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter with approximately $142.9 million in cash and inve...
- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid’s focus on both neuromuscular and cardiac diseases - CHARLESTOWN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- S...
2023-09-22 15:00:17 ET More on the markets No Signs Of A Major Top Yet, Staying Long BofA strategists have changed their view of the S&P 500 target, up 4%. Quant stock news sentiment measure keeps improving - BofA Amazon, Disney, Boeing boosted in Wells F...
News, Short Squeeze, Breakout and More Instantly...
Solid Biosciences Inc. Company Name:
SLDB Stock Symbol:
NASDAQ Market:
Solid Biosciences Inc. Website:
2024-07-06 13:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the Company has been added to the broad-market Russell 3000 ® Index as ...